Comprehensive molecular characterization of gastric adenocarcinoma
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Gastric cancer is a leading cause of cancer deaths, but analysis of its molecular and clinical characteristics has been complicated by histological and aetiological heterogeneity. Here we describe a comprehensive molecular evaluation of 295 primary gastric adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project. We propose a molecular classification dividing gastric cancer into four subtypes: tumours positive for Epstein–Barr virus, which display recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, CD274 (also known as PD-L1) and PDCD1LG2 (also known as PD-L2); microsatellite unstable tumours, which show elevated mutation rates, including mutations of genes encoding targetable oncogenic signalling proteins; genomically stable tumours, which are enriched for the diffuse histological variant and mutations of RHOA or fusions involving RHO-family GTPase-activating proteins; and tumours with chromosomal instability, which show marked aneuploidy and focal amplification of receptor tyrosine kinases. Identification of these subtypes provides a roadmap for patient stratification and trials of targeted therapies. The Cancer Genome Atlas reports on molecular evaluation of 295 primary gastric adenocarcinomas and proposes a new classification of gastric cancers into 4 subtypes, which should help with clinical assessment and trials of targeted therapies. This contribution from The Cancer Genome Atlas (TCGA) project describes the molecular evaluation of 295 primary gastric adenocarcinomas. Based on the results, the authors propose a novel classification separating gastric cancers into four subtypes according to: Epstein–Barr virus positive status, microsatellite instability, chromosomal instability or genomic stability. Given the histologic and etiologic heterogeneity of gastric cancer identification of these subtypes, using a schema that can readily be applied to patient samples should help with patient stratification and trials of targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many of the miRNAs were also reported by a recent systems biology paper from TCGA in 2014 [34].”
From Bioinformatic Interrogation of 5p-arm and 3p-arm Specific miRNA Expression Using TCGA Datasets (2015) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The fusion of this evidence has prompted TCGA and the Asian Cancer Research Group (ACRG) to propose several molecular classifications [77,78].”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“The TP53/APC double knockout (DKO) organoid line was established in our previous studies by sequentially disrupting TP53 and APC37, two common oncogenic loci in gastric adenocarcinoma38,39, from non-neoplastic human gastric organoids (Fig. S1A).”
From Large-scale CRISPR screening in primary human 3D gastric organoids enables comprehensive dissection of gene-drug interactions (2025) · cites this paper as [38]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Fusobacterium spp. is important in the development and progression of gastrointestinal tumors1,19,34,35”
From RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach (2020) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Self-citationLAURÉN, P. (1965) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/apm.1965.64.1.31 · Cited by 6,133
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationWHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Cell Migration: Integrating Signals from Front to Back
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., & Horwitz, A. R. (2003) · Science · doi:10.1126/science.1092053 · Cited by 4,978
Helicobacter pylori Infection and the Development of Gastric Cancer
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa001999 · Cited by 4,465
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Research works printed but not linked: 2
- Ferlay, J. et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase 11, http://globocan.iarc.fr, accessed on January 15, 2014 (2013)
- The Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012) · DOI · Paper page
Cited by
Items 101–200 of 1,024
Daemen, A., Peterson, D., Sahu, N., McCord, R., Du, X., Liu, B., Kowanetz, K., Hong, R., Moffat, J., Gao, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501605112 · Cited by 398
Sun, T.-T., He, J., Liang, Q., Ren, L.-L., Yan, T.-T., Yu, T.-C., Tang, J.-Y., Bao, Y.-J., Hu, Y., Lin, Y., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0921 · Cited by 397
McLean, M. H., & El-Omar, E. M. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.143 · Cited by 395
Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach
Guideline Committee of the Korean Gastric Cancer Association (KGCA), D. W. G. &. R. P. (2019) · Journal of Gastric Cancer · doi:10.5230/jgc.2019.19.e8 · Cited by 392
Sathe, A., Grimes, S. M., Lau, B. T., Chen, J., Suarez, C., Huang, R. J., Poultsides, G., & Ji, H. P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3231 · Cited by 386
ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer
Jiang, Y., Zhang, Q., Hu, Y., Li, T., Yu, J., Zhao, L., Ye, G., Deng, H., Mou, T., Cai, S., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002116 · Cited by 458
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
Janjigian, Y. Y., Sanchez-Vega, F., Jonsson, P., Chatila, W. K., Hechtman, J. F., Ku, G. Y., Riches, J. C., Tuvy, Y., Kundra, R., Bouvier, N., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0787 · Cited by 375
Molecular classification of gastric cancer
Chia, N.-Y., & Tan, P. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw040 · Cited by 375
A panoply of errors: polymerase proofreading domain mutations in cancer
Rayner, E., van Gool, I. C., Palles, C., Kearsey, S. E., Bosse, T., Tomlinson, I., & Church, D. N. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.12 · Cited by 373
Janjigian, Y. Y., Maron, S. B., Chatila, W. K., Millang, B., Chavan, S. S., Alterman, C., Chou, J. F., Segal, M. F., Simmons, M. Z., Momtaz, P., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30169-8 · Cited by 362
Fibroblast growth factor receptors as treatment targets in clinical oncology
Katoh, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0115-y · Cited by 352
Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors
Saghafinia, S., Mina, M., Riggi, N., Hanahan, D., & Ciriello, G. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.082 · Cited by 357
Differential DNA mismatch repair underlies mutation rate variation across the human genome
Supek, F., & Lehner, B. (2015) · Nature · doi:10.1038/nature14173 · Cited by 350
Current developments in gastric cancer: from molecular profiling to treatment strategy
Alsina, M., Arrazubi, V., Diez, M., & Tabernero, J. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00703-w · Cited by 350
Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy
Chang, L., Chang, M., Chang, H. M., & Chang, F. (2018) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0000000000000575 · Cited by 345
Zhang, M., Hu, S., Min, M., Ni, Y., Lu, Z., Sun, X., Wu, J., Liu, B., Ying, X., & Liu, Y. (2021) · Gut · doi:10.1136/gutjnl-2019-320368 · Cited by 339
Increased global transcription activity as a mechanism of replication stress in cancer
Kotsantis, P., Silva, L. M., Irmscher, S., Jones, R. M., Folkes, L., Gromak, N., & Petermann, E. (2016) · Nature Communications · doi:10.1038/ncomms13087 · Cited by 336
The role of Epstein–Barr virus in epithelial malignancies
Tsao, S., Tsang, C. M., To, K., & Lo, K. (2015) · The Journal of Pathology · doi:10.1002/path.4448 · Cited by 337
Onco-Multi-OMICS Approach: A New Frontier in Cancer Research
Chakraborty, S., Hosen, M. I., Ahmed, M., & Shekhar, H. U. (2018) · BioMed Research International · doi:10.1155/2018/9836256 · Cited by 335
“The main TCGA-strategy of multi-OMICS integration involves genomics, epigenomics, and transcriptomics which has been successfully implemented in the investigation of various cancer types including testicular germ cell tumors [51], soft tissue sarcomas [58], gastrointestinal adenocarcinomas [59], clear cell renal cell…”
BackgroundGambardella, V., Castillo, J., Tarazona, N., Gimeno-Valiente, F., Martínez-Ciarpaglini, C., Cabeza-Segura, M., Roselló, S., Roda, D., Huerta, M., Cervantes, A., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102015 · Cited by 335
Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis
Nanki, K., Toshimitsu, K., Takano, A., Fujii, M., Shimokawa, M., Ohta, Y., Matano, M., Seino, T., Nishikori, S., Ishikawa, K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.027 · Cited by 332
Machine learning for multi-omics data integration in cancer
Cai, Z., Poulos, R. C., Liu, J., & Zhong, Q. (2022) · iScience · doi:10.1016/j.isci.2022.103798 · Cited by 327
“Bass et al. used iCluster and discovered four sub-types of gastric cancer, enabling better patient stratification and treatment planning (Bass et al., 2014). moCluster ( general-purpose ) (Meng et al., 2016) is also a joint latent variable-based machine learning model, and was benchmarked against…”
MethodHayakawa, Y., Ariyama, H., Stancikova, J., Sakitani, K., Asfaha, S., Renz, B. W., Dubeykovskaya, Z. A., Shibata, W., Wang, H., Westphalen, C. B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.003 · Cited by 328
Epigenetic drivers of tumourigenesis and cancer metastasis
Chatterjee, A., Rodger, E. J., & Eccles, M. R. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.004 · Cited by 328
Mimura, K., Teh, J. L., Okayama, H., Shiraishi, K., Kua, L., Koh, V., Smoot, D. T., Ashktorab, H., Oike, T., Suzuki, Y., et al. (2018) · Cancer Science · doi:10.1111/cas.13424 · Cited by 329
Human gastric cancer modelling using organoids
Seidlitz, T., Merker, S. R., Rothe, A., Zakrzewski, F., von Neubeck, C., Grützmann, K., Sommer, U., Schweitzer, C., Schölch, S., Uhlemann, H., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-314549 · Cited by 328
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z.-N., Teng, Q.-X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z.-S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 322
“From the TCGA molecular subtypes, most of the GC cases studied had different degrees of mutations in the PIK3CA gene and amplification of RTK genes such as EGFR and HER2.(41,168,169) Mutations of the PIK3CA gene are likely to be late and isolated events in GC.”
BackgroundInfluentialPerformance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS
Kautto, E. A., Bonneville, R., Miya, J., Yu, L., Krook, M. A., Reeser, J. W., & Roychowdhury, S. (2017) · Oncotarget · doi:10.18632/oncotarget.13918 · Cited by 316
Estimating the global burden of Epstein–Barr virus-related cancers
Wong, Y., Meehan, M. T., Burrows, S. R., Doolan, D. L., & Miles, J. J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03824-y · Cited by 314
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
Pectasides, E., Stachler, M. D., Derks, S., Liu, Y., Maron, S., Islam, M., Alpert, L., Kwak, H., Kindler, H., Polite, B., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0395 · Cited by 307
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
Derks, S., Liao, X., Chiaravalli, A. M., Xu, X., Camargo, M. C., Solcia, E., Sessa, F., Fleitas, T., Freeman, G. J., Rodig, S. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9076 · Cited by 308
TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packages
Silva, T. C., Colaprico, A., Olsen, C., D'Angelo, F., Bontempi, G., Ceccarelli, M., & Noushmehr, H. (2016) · F1000Research · doi:10.12688/f1000research.8923.1 · Cited by 306
Dong, P., Xiong, Y., Yue, J., Hanley, S. J. B., & Watari, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00386 · Cited by 305
Proteogenomic Characterization of Human Early-Onset Gastric Cancer
Mun, D.-G., Bhin, J., Kim, S., Kim, H., Jung, J. H., Jung, Y., Jang, Y. E., Park, J. M., Kim, H., Jung, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.003 · Cited by 294
Self-citationAli, H. R., Glont, S.-E., Blows, F. M., Provenzano, E., Dawson, S.-J., Liu, B., Hiller, L., Dunn, J., Poole, C. J., Bowden, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv192 · Cited by 304
Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry
Huang, Y.-K., Wang, M., Sun, Y., Di Costanzo, N., Mitchell, C., Achuthan, A., Hamilton, J. A., Busuttil, R. A., & Boussioutas, A. (2019) · Nature Communications · doi:10.1038/s41467-019-11788-4 · Cited by 301
Nakamura, Y., Kawazoe, A., Lordick, F., Janjigian, Y. Y., & Shitara, K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00492-2 · Cited by 298
Takahashi-Kanemitsu, A., Knight, C. T., & Hatakeyama, M. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0339-5 · Cited by 299
Huang, K. K., Ramnarayanan, K., Zhu, F., Srivastava, S., Xu, C., Tan, A. L. K., Lee, M., Tay, S., Das, K., Xing, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.018 · Cited by 294
Ericksen, R. E., Lim, S. L., McDonnell, E., Shuen, W. H., Vadiveloo, M., White, P. J., Ding, Z., Kwok, R., Lee, P., Radda, G. K., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.12.020 · Cited by 295
Epstein-Barr virus and nasopharyngeal carcinoma
Young, L. S., & Dawson, C. W. (2014) · Chinese Journal of Cancer · doi:10.5732/cjc.014.10197 · Cited by 253
Integrative multi-omics approaches in cancer research: from biological networks to clinical subtypes
Heo, Y. J., Hwa, C., Lee, G.-H., Park, J.-M., & An, J.-Y. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0042 · Cited by 294
“…mutations, 2) a microsatellite-unstable subtype with a high mutation rate, 3) a genomically stable type enriched in a diffuse histological variant, and 4) a chromosomally unstable type with aneuploidy and focal amplification of receptor tyrosine kinases (Cancer Genome Atlas Research Network, 2014).”
BackgroundInfluentialPolom, K., Marano, L., Marrelli, D., De Luca, R., Roviello, G., Savelli, V, Tan, P., & Roviello, F. (2018) · Journal of British Surgery · doi:10.1002/bjs.10663 · Cited by 292
Inflammation-Induced Tumorigenesis and Metastasis
Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata-Yanagimoto, M., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115421 · Cited by 290
A proteomic landscape of diffuse-type gastric cancer
Ge, S., Xia, X., Ding, C., Zhen, B., Zhou, Q., Feng, J., Yuan, J., Chen, R., Li, Y., Ge, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03121-2 · Cited by 288
Johanns, T. M., Miller, C. A., Dorward, I. G., Tsien, C., Chang, E., Perry, A., Uppaluri, R., Ferguson, C., Schmidt, R. E., Dahiya, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0575 · Cited by 289
Muro, K., Lordick, F., Tsushima, T., Pentheroudakis, G., Baba, E., Lu, Z., Cho, B. C., Nor, I. M., Ng, M., Chen, L. T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy498 · Cited by 289
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
Kim, T.-H., Kim, I.-H., Kang, S. J., Choi, M., Kim, B.-H., Eom, B. W., Kim, B. J., Min, B.-H., Choi, C. I., Shin, C. M., et al. (2023) · Journal of Gastric Cancer · doi:10.5230/jgc.2023.23.e11 · Cited by 288
PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
Böger, C., Behrens, H.-M., Mathiak, M., Krüger, S., Kalthoff, H., & Röcken, C. (2016) · Oncotarget · doi:10.18632/oncotarget.8169 · Cited by 287
Update on Epstein-Barr virus and gastric cancer (Review)
SHINOZAKI-USHIKU, A., KUNITA, A., & FUKAYAMA, M. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2856 · Cited by 286
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Wong, G. S., Zhou, J., Liu, J. B., Wu, Z., Xu, X., Li, T., Xu, D., Schumacher, S. E., Puschhof, J., McFarland, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0022-x · Cited by 266
Targeted Therapies in Advanced Gastric Cancer
Patel, T. H., & Cecchini, M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00774-4 · Cited by 282
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
Lee, V., Murphy, A., Le, D. T., & Diaz, L. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0046 · Cited by 283
Zhang, C., Zhang, M., Ge, S., Huang, W., Lin, X., Gao, J., Gong, J., & Shen, L. (2019) · Cancer Medicine · doi:10.1002/cam4.2360 · Cited by 283
A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data
Mo, Q., Shen, R., Guo, C., Vannucci, M., Chan, K. S., & Hilsenbeck, S. G. (2018) · Biostatistics · doi:10.1093/biostatistics/kxx017 · Cited by 280
Dohlman, A. B., Arguijo Mendoza, D., Ding, S., Gao, M., Dressman, H., Iliev, I. D., Lipkin, S. M., & Shen, X. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.12.001 · Cited by 277
“[PubMed: 25079317] Cancer Genome Atlas Research Network; Albert Einstein College of Medicine; Analytical Biological Service; Barretos Cancer Hospital; Baylor College of Medicine; Beckman Research Institute of City of Hope; Buck Institute for Research on Aging; Canada’s Michael Smith Genome Sciences Center; Harvard Med…”
BackgroundMethodInfluentialPearson, A., Smyth, E., Babina, I. S., Herrera-Abreu, M. T., Tarazona, N., Peckitt, C., Kilgour, E., Smith, N. R., Geh, C., Rooney, C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1246 · Cited by 276
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
Gu, L., Chen, M., Guo, D., Zhu, H., Zhang, W., Pan, J., Zhong, X., Li, X., Qian, H., & Wang, X. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182692 · Cited by 280
Rho GTPase signaling in cancer progression and dissemination
Crosas-Molist, E., Samain, R., Kohlhammer, L., Orgaz, J. L., George, S. L., Maiques, O., Barcelo, J., & Sanz-Moreno, V. (2022) · Physiological Reviews · doi:10.1152/physrev.00045.2020 · Cited by 272
Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease−Associated Colorectal Cancers
Robles, A. I., Traverso, G., Zhang, M., Roberts, N. J., Khan, M. A., Joseph, C., Lauwers, G. Y., Selaru, F. M., Popoli, M., Pittman, M. E., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.036 · Cited by 276
Lgr5-expressing chief cells drive epithelial regeneration and cancer in the oxyntic stomach
Leushacke, M., Tan, S. H., Wong, A., Swathi, Y., Hajamohideen, A., Tan, L. T., Goh, J., Wong, E., Denil, S. L. I. J., Murakami, K., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3541 · Cited by 274
Sun, J. X., He, Y., Sanford, E., Montesion, M., Frampton, G. M., Vignot, S., Soria, J.-C., Ross, J. S., Miller, V. A., Stephens, P. J., et al. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005965 · Cited by 273
Wang, R., Dang, M., Harada, K., Han, G., Wang, F., Pool Pizzi, M., Zhao, M., Tatlonghari, G., Zhang, S., Hao, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-1125-8 · Cited by 267
Kawazoe, A., Fukuoka, S., Nakamura, Y., Kuboki, Y., Wakabayashi, M., Nomura, S., Mikamoto, Y., Shima, H., Fujishiro, N., Higuchi, T., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30271-0 · Cited by 269
Yasuda, T., & Wang, Y. A. (2024) · Trends in Cancer · doi:10.1016/j.trecan.2024.03.008 · Cited by 261
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Molecular Pathways: Targeting ATR in Cancer Therapy
Karnitz, L. M., & Zou, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0479 · Cited by 265
The kinome 'at large' in cancer
Fleuren, E. D. G., Zhang, L., Wu, J., & Daly, R. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.18 · Cited by 264
Cytokinesis defects and cancer
Lens, S. M. A., & Medema, R. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0084-6 · Cited by 264
Hao, J.-J., Lin, D.-C., Dinh, H. Q., Mayakonda, A., Jiang, Y.-Y., Chang, C., Jiang, Y., Lu, C.-C., Shi, Z.-Z., Xu, X., et al. (2016) · Nature Genetics · doi:10.1038/ng.3683 · Cited by 259
Kumagai, S., Togashi, Y., Sakai, C., Kawazoe, A., Kawazu, M., Ueno, T., Sato, E., Kuwata, T., Kinoshita, T., Yamamoto, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.016 · Cited by 257
Intratumoural microbiota: a new frontier in cancer development and therapy
Cao, Y., Xia, H., Tan, X., Shi, C., Ma, Y., Meng, D., Zhou, M., Lv, Z., Wang, S., & Jin, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01693-0 · Cited by 253
Li, S., Yu, W., Xie, F., Luo, H., Liu, Z., Lv, W., Shi, D., Yu, D., Gao, P., Chen, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35431-x · Cited by 253
Liquid–liquid phase separation in tumor biology
Tong, X., Tang, R., Xu, J., Wang, W., Zhao, Y., Yu, X., & Shi, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01076-x · Cited by 252
Bartley, A. N., Washington, M. K., Ventura, C. B., Ismaila, N., Colasacco, C., Benson, A. B., Carrato, A., Gulley, M. L., Jain, D., Kakar, S., et al. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0331-cp · Cited by 254
Gong, J., Li, Y., Liu, C.-J., Xiang, Y., Li, C., Ye, Y., Zhang, Z., Hawke, D. H., Park, P. K., Diao, L., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.070 · Cited by 249
Poornima, P., Kumar, J. D., Zhao, Q., Blunder, M., & Efferth, T. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.018 · Cited by 248
White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer
Leal, A., van Grieken, N. C. T., Palsgrove, D. N., Phallen, J., Medina, J. E., Hruban, C., Broeckaert, M. A. M., Anagnostou, V., Adleff, V., Bruhm, D. C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14310-3 · Cited by 244
Gastric cancer: Epidemiology, risk factors and prevention strategies
Yang, L., Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), B. O. F. C. P. A. C., Ying, X., Liu, S., Lyu, G., Xu, Z., Zhang, X., Li, H., Li, Q., Wang, N., et al. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2020.06.03 · Cited by 244
Hudson, K., Cross, N., Jordan-Mahy, N., & Leyland, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.568931 · Cited by 243
“In addition, copy number gains are also less frequently observed in gastric cancer (15%) (86), NSCLC (5.”
BackgroundTargeting JAK kinase in solid tumors: emerging opportunities and challenges
Buchert, M., Burns, C. J., & Ernst, M. (2016) · Oncogene · doi:10.1038/onc.2015.150 · Cited by 243
Kwon, M., An, M., Klempner, S. J., Lee, H., Kim, K.-M., Sa, J. K., Cho, H. J., Hong, J. Y., Lee, T., Min, Y. W., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0219 · Cited by 237
Echizen, K., Hirose, O., Maeda, Y., & Oshima, M. (2016) · Cancer Science · doi:10.1111/cas.12901 · Cited by 238
Choi, Y. Y., Kim, H., Shin, S.-J., Kim, H. Y., Lee, J., Yang, H.-K., Kim, W. H., Kim, Y.-W., Kook, M.-C., Park, Y. K., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000002803 · Cited by 239
Targeting Rac and Cdc42 GTPases in Cancer
Maldonado, M. D. M., & Dharmawardhane, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0619 · Cited by 237
MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway
Guan, J., Lu, C., Jin, Q., Lu, H., Chen, X., Tian, L., Zhang, Y., Ortega, J., Zhang, J., Siteni, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.004 · Cited by 237
Katoh, M. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3689 · Cited by 211
Zeng, D., Wu, J., Luo, H., Li, Y., Xiao, J., Peng, J., Ye, Z., Zhou, R., Yu, Y., Wang, G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002467 · Cited by 236
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
Xiong, J., Cui, B.-W., Wang, N., Dai, Y.-T., Zhang, H., Wang, C.-F., Zhong, H.-J., Cheng, S., Ou-Yang, B.-S., Hu, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.005 · Cited by 233
Pavlakis, N., Sjoquist, K. M., Martin, A. J., Tsobanis, E., Yip, S., Kang, Y.-K., Bang, Y.-J., Alcindor, T., O’Callaghan, C. J., Burnell, M. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.1901 · Cited by 232
the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Frankell, A. M., Jammula, S., Li, X., Contino, G., Killcoyne, S., Abbas, S., Perner, J., Bower, L., Devonshire, G., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0331-5 · Cited by 231
Ishimoto, T., Miyake, K., Nandi, T., Yashiro, M., Onishi, N., Huang, K. K., Lin, S. J., Kalpana, R., Tay, S. T., Suzuki, Y., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.046 · Cited by 233
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
Chabanon, R. M., Pedrero, M., Lefebvre, C., Marabelle, A., Soria, J.-C., & Postel-Vinay, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0903 · Cited by 230
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
Zhang, J., Dang, F., Ren, J., & Wei, W. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.09.004 · Cited by 229
Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
Maron, S. B., Chase, L. M., Lomnicki, S., Kochanny, S., Moore, K. L., Joshi, S. S., Landron, S., Johnson, J., Kiedrowski, L. A., Nagy, R. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1704 · Cited by 229
Cancer proteogenomics: current impact and future prospects
Mani, D. R., Krug, K., Zhang, B., Satpathy, S., Clauser, K. R., Ding, L., Ellis, M., Gillette, M. A., & Carr, S. A. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00446-5 · Cited by 229
Lee, J., Kim, S. T., Kim, K., Lee, H., Kozarewa, I., Mortimer, P. G. S., Odegaard, J. I., Harrington, E. A., Lee, J., Lee, T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0442 · Cited by 228
Bhat, M. I., & Kapila, R. (2017) · Nutrition Reviews · doi:10.1093/nutrit/nux001 · Cited by 228
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
on behalf of the MErCuRIC consortium, Bradley, C. A., Salto-Tellez, M., Laurent-Puig, P., Bardelli, A., Rolfo, C., Tabernero, J., Khawaja, H. A., Lawler, M., Johnston, P. G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.40 · Cited by 225
The crucial role of multiomic approach in cancer research and clinically relevant outcomes
Lu, M., & Zhan, X. (2018) · EPMA Journal · doi:10.1007/s13167-018-0128-8 · Cited by 224
“TCGA research network has showed the comprehensive genomic characterization of squamous cell lung cancers [44], gastric adenocarcinoma [45], human colon and rectal cancer [46], human glioblastoma [47], and ovarian carcinoma [48].”
Background
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-23
- Volume
- 513
- Issue
- 7517
- Pages
- 202-209
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4170219
- OpenAlex
- W2126547130
- Cited by
- 6,498
- References
- 43
- Citations by year
- 2026: 455 · 2025: 481 · 2024: 569 · 2023: 637 · 2022: 620 · 2021: 737 · 2020: 653 · 2019: 554 · 2018: 560 · 2017: 490 · 2016: 398 · 2015: 297 · 2014: 41
- FWCI
- 327.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- KUMeL Repository (Keimyung University) (submittedVersion, cc-by-nc-nd)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, R01HG007069, U54HG003079, U54HG003273, R01HG005690)
- National Cancer Institute (P30CA16672, K08CA134931, P50CA098258, U24CA143882, P01CA028842, R01CA180006, U24CA143843, U24CA143840, U24CA143858, U24CA126543, U24CA144025, U24CA143866, U24CA143883, U24CA143845, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA143835, K99CA166729, P30CA008748, P30CA016672, P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Keywords
- gastric adenocarcinoma, molecular classification, Epstein-Barr virus, PIK3CA mutation, DNA hypermethylation, PD-L1, PD-L2, microsatellite instability, chromosomal instability, genome stability, RHOA mutations, aneuploidy, targeted therapy, patient stratification
- MeSH terms
- Adenocarcinoma, Herpesvirus 4, Human, Female, Humans, Male, Mutation, Stomach Neoplasms, Genome, Human, Gene Expression Regulation, Neoplastic, Proteome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.